Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system

Clinical Therapeutics

Volumn 32, Issue 7, 2010, Pages 1343-1356

  Neubauer, Aljoscha S ^a   Holz, Frank G ^b   Sauer, Stefan ^c   Wasmuth, Timo ^c   Hirneiss, Christoph ^a   Kampik, Anselm ^a   Schrader, Wolfgang ^d,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d Maximilians Augenklinik   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Choroidal neovascularization; Cost utility; Germany; Macular degeneration; QALY; Quality adjusted life year; Ranibizumab; Value based medicine

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; GERMANY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PHOTODYNAMIC THERAPY; PROBABILITY; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; DRUG COSTS; GERMANY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MACULAR DEGENERATION; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 77955302618     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.010     Document Type: Article

References (55)

1. Lotery A, Xu X, Zlatava G, Loftus J Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: Results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007, 91:1303-1307.
2. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: Findings of a multicountry study. Arch Ophthalmol. 2007, 125:1249-1254.
3. Brown MM, Brown GC, Sharma S, et al. The burden of age-related macular degeneration: A value-based analysis [published correction appears in Curr Opin Ophthalmol. 2006;17:265]. Curr Opin Ophthalmol. 2006, 17:257-266.
4. Knauer C, Pfeiffer N Blindness in Germanytoday and in 2030 [in German]. Ophthalmologe. 2006, 103:735-741.
5. Hirneiss C, Neubauer AS, Welge-Lssen U, et al. Measuring patient's quality of life in ophthalmology [in German]. Ophthalmologe. 2003, 100:1091-1097.
6. Schrader WF Age-related macular degeneration: A socioeconomic time bomb in our aging society [in German]. Ophthalmologe. 2006, 103:742-748.
7. Lucentis (ranibizumab injection) [package insert] 2010, Genentech, Inc, South San Francisco, Calif.
8. Macugen (pegaptanib sodium injection) [package insert] 2008, Eyetech, Inc, Cedar Knolls, NJ.
9. Avastin (bevacizumab) [package insert] 2009, Genentech, Inc, South San Francisco, Calif.
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1432-1444. ANCHOR Study Group.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006, 355:1419-1431. MARINA Study Group.
12. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photo-dynamic therapy for neovascular agerelated macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009, 116:57-65. ANCHOR Study Group.
13. Hernndez-Pastor LJ, Ortega A, Garca-Layana A, Girldez J Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010, 248:467-476.
14. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 2008, 12:iii-iv.
15. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 2008, 12:ix-201.
16. Brown GC, Brown MM, Brown HC, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 2007, 114:1170-1178.
17. Laupacis A, Feeny D, Detsky AS, Tugwell PX How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992, 146:473-481.
18. Cohen SY, Bremond-Gignac D, Quentel G, et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2008, 246:1527-1534.
19. Institute for Quality and Efficiency in Health Care Accessed January 17, 2010. http://www.iqwig.de/cost-benefit-assessment.736.en.html.
20. Brown MM, Brown GC, Brown HC, et al. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions. Curr Opin Ophthalmol. 2008, 19:202-207.
21. Marback RF, Maia OO, Morais FB, Takahashi WY Quality of life in patients with age-related macular degeneration with monocular and binocular legal blindness. Clinics (Sao Paulo). 2007, 62:573-578.
22. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001, 85:327-331.
23. Brown GC, Brown MM Comparative effectiveness. Curr Opin Ophthalmol. 2009, 20:147-150.
24. Brown MM, Luo B, Brown HC, Brown GC Comparative effectiveness: Its role in the healthcare system. Curr Opin Ophthalmol. 2009, 20:188-194.
25. Brown GC, Sharma S, Brown MM, Kistler J Utility values and age-related macular degeneration. Arch Ophthalmol. 2000, 118:47-51.
26. Bansback N, Czoski-Murray C, Carlton J, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: The association of contrast sensitivity and visual acuity. Qual Life Res. 2007, 16:533-543.
27. Bansback N, Davis S, Brazier J Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye (Lond). 2007, 21:1455-1463.
28. Neubauer AS, Holz FG, Schrader W, et al. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration [in German]. Klin Monbl Augenheilkd. 2007, 224:727-732.
29. Malamos P, Sacu S, Georgopoulos M, et al. Correlation of highdefinition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci. 2009, 50:4926-4933.
30. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol. 1991, 109:1242-1257. Macular Photocoagulation Study Group.
31. Meyer CH, Helb HM, Eter N Monitoring of AMD patients on antivascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series [in German]. Ophthalmologe 2008, 105:125-138.
32. Meyer CH, Helb HM, Eter N Monitoring of AMD patients on antivascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series [in German]. Ophthalmologe 2008, 105:140-142.
33. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomographyguided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007, 143:566-583.
34. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009, 148:43-58.
35. German Drug Information. Red List [in German] Accessed June 27, 2010. http://www.roteliste.de.
36. Kassernrztliche Bundesverinigung Accessed June 27, 2010. http://www.ebm2000plus.de.
37. Institute for the Hospital Payment System [in German] Accessed June 27, 2010. http://www.g-drg.de.
38. Cruess AF, Zlateva G, Xu X, et al. Economic burden of bilateral neovascular age-related macular degeneration: Multi-country observational study. PharmacoEconomics. 2008, 26:57-73.
39. Meads C, Hyde C What is the cost of blindness?. Br J Ophthalmol. 2003, 87:1201-1204.
40. Pfau N, Kupsch S, Kern AO, Beske F Epidemiology and Socioeconomic Importance of Blindness and Severe Visual Impairment in Germany [in German] 2000, Kiel Institute for Health Care Systems Research GmbH, Triltsch Ochsenfurt, Ochsen-furt, Germany.
41. Pauleikhoff D, Scheider A, Wiedmann P, et al. Neovascular agerelated macular degeneration in Germany: Encroachment on the quality of life and the financial implications [in German]. Ophthalmologe. 2009, 106:242-251.
42. Federal Office for Statistics. German Death Tables 2005/2007, Accessed August 22, 2008. http://www.destatis.de.
43. Brown GC, Brown MM, Campanella J, Beauchamp GR The costutility of photodynamic therapy in eyes with neovascular macular degenerationa value-based reappraisal with 5-year data. Am J Ophthalmol. 2005, 140:679-687.
44. Mantel I, Zografos L, Ambresin A Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in agerelated macular degeneration. Ophthalmologica. 2008, 222:321-323.
45. Rosenfeld PJ, Rich RM, Lalwani GA Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006, 19:361-372.
46. Fletcher EC, Lade RJ, Adewoyin T, Chong NV Computerized model of costutility analysis for treatment of age-related macular degeneration. Ophthalmology. 2008, 115:2192-2198.
47. Hopley C, Salkeld G, Mitchell P Cost utility of photodynamic therapy for predominantly classic neo-vascular age related macular degeneration. Br J Ophthalmol. 2004, 88:982-987.
48. Brown GC, Brown MM, Sharma S, et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology. 2000, 107:1374-1380.
49. Busbee BG, Brown MM, Brown CG, Sharma S CME review: A costutility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003, 23:279-287.
50. Busbee BG, Brown MM, Brown CG, Sharma S CME review: A costutility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003, 23:443-444. quiz.
51. X-rates. 2010Euros to 1 USD Accessed June 2010. http://www.x-rates.com/d/EUR/USD/hist2010.html.
52. Brown MM, Brown GC, Brown HC, Peet J A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008, 115:1039-1045.
53. Gower EW, Cassard SD, Bass EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration. Retina. 2010, 30:212-221.
54. Brown MM, Brown GC, Sharma S, et al. Quality of life associated with unilateral and bilateral good vision. Ophthalmology 2001, 108:643-647.
55. Brown MM, Brown GC, Sharma S, et al. Quality of life associated with unilateral and bilateral good vision. Ophthalmology 2001, 108:647-648. discussion.